Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANCO A FELIZARTA

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1629004957
CMS profile
118409
Location
BAKERSFIELD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$61,010.19

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $30,138.46 49
Gilead Sciences, Inc. $22,710.00 46
ABBVIE INC. $5,287.66 30
Merck Sharp & Dohme LLC $1,832.53 8
Theratechnologies Inc. $605.93 2
Astellas Pharma US Inc $142.88 4
Shionogi Inc $141.82 6
Janssen Biotech, Inc. $133.34 5
Insmed, Inc. $17.57 1

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANCO A FELIZARTA

NPI 1629004957 · CMS profile ID 118409

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

BAKERSFIELD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629004957?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANCO A FELIZARTA, NPI 1629004957, CMS profile ID 118409. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629004957?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). FRANCO A FELIZARTA, NPI 1629004957, CMS profile ID 118409. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629004957?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
FRANCO A FELIZARTA, NPI 1629004957, CMS profile ID 118409, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1629004957?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $61,010.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Shionogi Inc $30.7509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051756417 CMS
Gilead Sciences, Inc. $11.4809/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026061755 CMS
Astellas Pharma US Inc $12.8009/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034488535 CMS
Gilead Sciences, Inc. $23.9309/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025675351 CMS
Astellas Pharma US Inc $24.9009/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034472759 CMS
Gilead Sciences, Inc. $6.8808/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026100781 CMS
Janssen Biotech, Inc. $29.8008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988176549 CMS
Merck Sharp & Dohme LLC $25.8608/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048890667 CMS
ABBVIE INC. $21.4808/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240411 CMS
Janssen Biotech, Inc. $35.2708/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988176559 CMS
ViiV Healthcare Company $16.2408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209075 CMS
ViiV Healthcare Company $32.2408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211187 CMS
ABBVIE INC. $16.6008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240409 CMS
ViiV Healthcare Company $2,600.0008/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209689 CMS
ABBVIE INC. $22.1307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240407 CMS
ViiV Healthcare Company $3,900.0007/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209087 CMS
ViiV Healthcare Company $1,950.0007/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209107 CMS
ViiV Healthcare Company $3,900.0007/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210277 CMS
Gilead Sciences, Inc. $23.2207/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025701143 CMS
ViiV Healthcare Company $19.0007/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211973 CMS
ViiV Healthcare Company $3,900.0007/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211571 CMS
ABBVIE INC. $1,750.0007/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240405 CMS
ViiV Healthcare Company $20.7807/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210703 CMS
Gilead Sciences, Inc. $33.0606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025547545 CMS
Gilead Sciences, Inc. $25.1006/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025633052 CMS
ABBVIE INC. $123.9506/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240403 CMS
ABBVIE INC. $31.1206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240401 CMS
ViiV Healthcare Company $71.4006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001212065 CMS
ViiV Healthcare Company $8.0006/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209701 CMS
ViiV Healthcare Company $16.6406/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209747 CMS
ViiV Healthcare Company $84.6306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209783 CMS
ViiV Healthcare Company $25.0006/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210265 CMS
ViiV Healthcare Company $13.4606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210289 CMS
ViiV Healthcare Company $765.7206/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211547 CMS
ViiV Healthcare Company $344.9106/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211983 CMS
ViiV Healthcare Company $25.0006/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001212029 CMS
Merck Sharp & Dohme LLC $25.4506/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048825233 CMS
Gilead Sciences, Inc. $24.6006/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025652161 CMS
Shionogi Inc $8.5905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051756391 CMS
Janssen Biotech, Inc. $16.0705/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988176575 CMS
ViiV Healthcare Company $6.2605/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211151 CMS
ViiV Healthcare Company $1,300.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210691 CMS
ViiV Healthcare Company $3.8505/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211175 CMS
Gilead Sciences, Inc. $4,060.0005/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035829383 CMS
ViiV Healthcare Company $25.8005/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211583 CMS
Shionogi Inc $24.3805/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051756373 CMS
ViiV Healthcare Company $29.9905/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209099 CMS
Gilead Sciences, Inc. $24.4205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025658207 CMS
ABBVIE INC. $1,050.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997240399 CMS
Merck Sharp & Dohme LLC $26.6605/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048566883 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $89,860.96 217
PY2020 $47,624.41 125
PY2021 $46,157.78 88
PY2022 $63,174.96 138
PY2023 $61,010.19 151
PY2024 $74,948.78 170
PY2025 $57,242.65 111

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,488.00 3
PY2025 Principal investigator $229,442.19 44
PY2024 Recipient $34,457.05 7
PY2024 Principal investigator $538,200.10 105
PY2023 Recipient $3,955.93 8
PY2023 Principal investigator $328,545.59 66
PY2022 Recipient $14,870.00 15
PY2022 Principal investigator $439,960.49 96
PY2021 Recipient $112,279.50 7
PY2021 Principal investigator $616,562.85 149
PY2020 Recipient $148,768.08 16
PY2020 Principal investigator $492,259.57 200
PY2019 Recipient $117,699.19 15
PY2019 Principal investigator $431,099.44 120

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ViiV Healthcare Company $4,005.45 12/08/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316787
Principal investigator 1 ViiV Healthcare Company $746.55 12/03/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316779
Principal investigator 1 ViiV Healthcare Company $1,283.04 12/01/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316785
Principal investigator 1 ViiV Healthcare Company $2,781.14 11/24/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316279
Principal investigator 1 ABBVIE INC. $18,204.24 11/04/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520113
Principal investigator 1 ViiV Healthcare Company $219.29 10/28/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD-BAKERSFIELD-UNITED S
A RANDOMIZED, DOUBLE-BLIND (SPONSOR-UNBLINDED), PLACEBO-CONTROLLED, AD No dispute reported 06/30/2026 1190316715
Principal investigator 1 ViiV Healthcare Company $4,924.39 09/24/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316223
Principal investigator 1 ViiV Healthcare Company $9,701.77 09/18/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316271
Principal investigator 1 ViiV Healthcare Company $1,471.50 08/06/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316781
Principal investigator 1 ABBVIE INC. $2,276.10 08/05/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202501132
Principal investigator 1 ViiV Healthcare Company $203.03 07/23/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316721
Principal investigator 1 ViiV Healthcare Company $9,180.54 07/21/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316275
Principal investigator 1 ViiV Healthcare Company $1,283.04 07/09/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318969
Principal investigator 1 ABBVIE INC. $8,700.77 07/02/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202495265
Principal investigator 1 ABBVIE INC. $10,550.00 06/26/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202493273
Principal investigator 1 ViiV Healthcare Company $225.72 06/26/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, PH No dispute reported 06/30/2026 1190316227
Principal investigator 1 ViiV Healthcare Company $9,721.21 06/22/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316281
Principal investigator 1 ViiV Healthcare Company $17,305.24 05/16/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316273
Principal investigator 1 ViiV Healthcare Company $1,500.00 05/16/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190316719
Principal investigator 1 ViiV Healthcare Company $733.86 05/16/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318977
Principal investigator 1 ABBVIE INC. $5,613.65 05/06/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202481657
Principal investigator 1 ViiV Healthcare Company $6,870.82 04/28/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316277
Recipient Gilead Sciences, Inc. $1,138.00 04/22/2025 Covered Recipient Physician A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202276
Principal investigator 1 ViiV Healthcare Company $1,009.66 04/11/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318979
Principal investigator 1 ViiV Healthcare Company $8,874.36 03/21/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316711
Principal investigator 1 ABBVIE INC. $4,323.72 03/07/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202460085
Principal investigator 1 ViiV Healthcare Company $29,554.51 03/05/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190316707
Principal investigator 1 ViiV Healthcare Company $1,200.00 02/25/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, PH No dispute reported 06/30/2026 1190316219
Principal investigator 1 ViiV Healthcare Company $9,440.72 02/25/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190316269
Principal investigator 1 ViiV Healthcare Company $500.00 02/25/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, PH No dispute reported 06/30/2026 1190316709
Principal investigator 1 ViiV Healthcare Company $1,500.00 02/25/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, PH No dispute reported 06/30/2026 1190316713
Principal investigator 1 ViiV Healthcare Company $5,218.44 02/21/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316789
Recipient Gilead Sciences, Inc. $1,138.00 02/19/2025 Covered Recipient Physician A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202269
Principal investigator 1 ViiV Healthcare Company $550.39 02/19/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316791
Principal investigator 1 ViiV Healthcare Company $21,420.45 02/11/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316221
Principal investigator 1 ABBVIE INC. $5,132.03 02/06/2025 Non-covered Recipient Entity
FRANCO ANTONIO BALAMBAN FELIZARTA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202447147
Principal investigator 1 ViiV Healthcare Company $206.55 02/05/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190316717
Principal investigator 1 ViiV Healthcare Company $476.55 02/05/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316783
Principal investigator 1 ViiV Healthcare Company $5,125.08 01/29/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318973
Principal investigator 1 GlaxoSmithKline, LLC. $923.67 01/28/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192133406
Principal investigator 1 ViiV Healthcare Company $56.79 01/28/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, ST No dispute reported 06/30/2026 1190316215
Principal investigator 1 ViiV Healthcare Company $154.35 01/28/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A RANDOMIZED, DOUBLE-BLIND (SPONSOR UNBLINDED), PLACEBO-CONTROLLED, ST No dispute reported 06/30/2026 1190316217
Principal investigator 1 ViiV Healthcare Company $8,587.62 01/24/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318975
Recipient Gilead Sciences, Inc. $1,212.00 01/22/2025 Covered Recipient Physician A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202263
Principal investigator 1 ViiV Healthcare Company $2,857.95 01/10/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318971
Principal investigator 1 ViiV Healthcare Company $4,256.14 01/08/2025 Non-covered Recipient Entity
FRANCO FELIZARTA MD
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190316225
Principal investigator 1 ViiV Healthcare Company $571.86 01/08/2025 Non-covered Recipient Entity
FELIZARTA FRANCO A OFFICE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190316777